Erytech is a biopharmaceutical company developing innovative therapies to target unmet medical needs, particularly in the fields of cancer and orphan diseases. Erytech’s proprietary technology is based on encapsulation of therapeutic molecules into red blood cells. Encapsulation offers a number of benefits as compared to free-form compounds, reducing the potential for allergic reactions and allowing the therapeutic substance to remain longer in the body. The Company's product provides a therapeutic solution to patients with relapsed and refractory acute lymphoblastic leukemia.
Type
Public
HQ
Lyon, FR
Founded
2004
Size (employees)
94 (est)+11%
Erytech Pharma was founded in 2004 and is headquartered in Lyon, FR
Report incorrect company information

Erytech Pharma Office Locations

Erytech Pharma has offices in Lyon and Cambridge
Lyon, FR (HQ)
60 avenue Rockefeller
Show all (2)
Report incorrect company information

Erytech Pharma Financials and Metrics

Erytech Pharma Financials

Market capitalization (31-Oct-2017)

291.3 m

Closing share price (31-Oct-2017)

24.7
Erytech Pharma's current market capitalization is €291.3 m.
Show all financial metrics
Report incorrect company information

Erytech Pharma News and Updates

Erytech Pharma sets IPO pricing terms

Erytech Pharma, a French biopharmaceutical company, has priced its IPO of up to 4.26 million shares at between $23 and $24 per share. Erytech plans on listing the stock on the NASDAQ under the ticker symbol “ERYP.” Jefferies and Cowen & Company are among the underwriters. Erytech’s backers inclu…
Report incorrect company information